Efficacy and safety of the new drug against multiple sclerosis «PEGylated Interferon beta-1a Human» in monkeys compared with unmodified interferon beta-1a

The article presents the results of studies on the safety and efficacy of long-acting drug for the treatment of multiple sclerosis on the basis of recombinant human interferon beta-1a «PEGylated interferon beta-1a Human» (PEG IFN beta-1a) in monkeys Macaca mulatta in subcutaneous and intramuscular injection. The following doses were used: the maximum tolerated dose - 3.0·10⁶ IU/kg, the intermediate dose - 1.5·10⁶ IU/kg and the minimum dose, which was equivalent to human therapeutic dose of unmodified interferon beta-1a - 0.3·10⁶ IU/kg. Quantify the parameters of pharmacodynamics of the PEG IFN beta-1a after single subcutaneous and intramuscular administration of increasing doses of different groups of monkeys. Evaluated the level and nature of the pathological changes of internal organs (visceral systems) of experimental animals caused by repeated subcutaneous and intramuscular injections of PEG IFN-beta 1a. Based on these studies the drug PEG IFN beta-1a in rhesus monkeys indicated that the drug is efficient (both in single subcutaneous and intramuscular administration) and does not have toxic effects (both in multiple subcutaneous and intramuscular administration) when using a therapeutic dose 0.3·10⁶ IU/kg.

интерферон бета-1а, пегилированный интерферон бета-1а, рассеянный склероз, фармакодинамика, безопасность, эффективность, токсичность, interferon beta-1a, PEGylated interferon beta-1a, multiple sclerosis, pharmacodynamics, safety, efficiency, toxicity

1. Limmroth V, Putzki N, Kachuck NJ. The interferon beta therapies for treatment of relapsing remitting multiple sclerosis: are they equally efficacious? A comparative review of open label studies evaluating the efficacy, safety, or dosing of different interferon beta formulations alone or in combination. Ther Adv Neurol Disord. 2011; 4(5): 281–96.

2. Walther EU, Hohlfeld R. Multiple sclerosis: side effects of interferon therapy and their management. Neurology 1999; 53: 1622–7.

3. State Standard P 53434 – 2009. Principles of Good Laboratory Practice (in Russian).

4. On approval of the Rules of laboratory practices. Order of the Ministry of Health and Social Development of the Russian Federation dated August 23, 2010, ¹ 708n (in Russian).

5. Mironov AN, ed. Guidelines for conducting pre-clinical trials of medicinal products. Moscow: Grif i K; 2012 (in Russian).

6. Draft consensus guideline Addendum to ICH S6 — Preclinical safety evaluation of biotechnology-derived pharmaceuticals; 2009.

7. ICH S6 — Preclinical safety evaluation of biotechnology-derived pharmaceuticals; 1997.

8. Rejdak K, Leary SM, Stelmasiak Z, et al. Urinary nitric oxide metabolites and neopterin as markers of longitudinal interferon beta-1a treatment in primary progressive multiple sclerosis patients. Journal of the neurological sciences 2005; 238: 244.

9. Bagnato F, Durastanti V, Finamore L, Volante G, Millefiorini E. Beta-2 microglobulin and neopterin as markers of disease activity in multiple sclerosis. Neurol Sci 2003; 24: 301–4.

10. Matson MA, Zimmerman TR, Tuccillo D, Tang Y, Deykin A. Dose titration of intramuscular interferon beta-1a reduces the severity and incidence of flu-like symptoms during treatment. Curr Med Res Opin. 2011; 27(12): 2271–8.

11. Kuksova MI. Hematopoietic system of monkeys in health and disease. Moscow: Meditsina; 1972 (in Russian).

12. Tremlett HL, Oger J. Elevated aminotransferases during treatment with interferon-beta for multiple sclerosis: actions and outcomes. Mult Scler. 2004; 10: 298–301.

13. Kamphuis E, Junt T, Waibler Z, Forster R, Kalinke U. Type I interferons directly regulate lymphocyte recirculation and cause transient blood lymphopenia. Blood 2006, 108: 3253–61.